A disruptive theory
Despite the enormous effort made over decades, all studies aimed at blocking Alzheimer's disease have failed. It is necessary to reconsider the current strategy to combat the disease.
The scientific theory developed by Tetraneuron involves a change of approach to address the treatment of this disease.
Research
Tetraneuron works actively on two lines of research, both derived from the phosphorylation of E2F4 during the earliest stages of Alzheimer's disease.
Our first line of research seeks the effective blockade of such phosphorylation and consequent neural tetraploidization as an effective therapy against Alzheimer's disease.
Our second line of research studies the presence of phosphorylated E2F4 in the blood serum as an early biomarker of Alzheimer's disease.
The possibility of having an early diagnosis of Alzheimer's disease and an effective therapeutic method against this pathology, both developed by our company, envisions a hopeful future against this neurodegenerative pathology.
About us
Tetraneuron is a private company founded in November 2012, which is developing a research project for the prevention of neuronal tetraploidy as a therapy for Alzheimer's disease.
The scientific team is led by Prof. José María Frade at the Cajal Institute, a reputed research institute belonging to the Higher Council for Scientific Research (CSIC), belonging to the Ministry of Science, Innovation and Universities of the Government of Spain.
Induction of cell death by endogenous nerve growth factor through its p75 receptor.
Nerve Growth Factor-Induced Cell Cycle Reentry in Newborn Neurons Is Triggered by p38MAPK-Dependent E2F4 Phosphorylation.
Somatic tetraploidy in specific chick retinal ganglion cells induced by nerve growth factor.
Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology.
De Noelia López-Sánchez a,b, Ángela Fontán-Lozano a, Anna Pallé a, Valentina González-Álvarez c, Alberto Rábano c, José L. Trejo a, José M. Frade
Download publication
A mutant form of E2F4 prevents neuronal tetraploidization and cognitive deficits in 5xFAD mice without affecting Abeta deposition.
Scientific Board of Advisors
Manuel Pérez-Alonso
President of the Spanish Association of Scientific Entrepreneurs.
Manuel Pérez Alonso has a degree in Biology and PhD in Molecular Genetics after a three-year stay in the Laboratory of Molecular Genetics at the University of Lund (Sweden). He is Professor of Genetics at the Universitat de València, where he founded the Laboratory of Molecular Genetics of Development. He is co-director of the Master in Medical Genetics and Genomics at the University of Valencia. In his university laboratory, he has developed more than twenty research projects funded by various national and international organisms, and three biotechnology patents that have been transferred to the biopharmaceutical industry. Among his contributions to the area of Genomics, his participation in three international genome sequencing consortia stands out.
He has been Roche's scientific advisor in the field of DNA sequencing. For twelve years, from its foundation in 1998 to April 2009, it has been the promoter and founding partner of the company Sistemas Genómicos SL, where he held the position of Scientific and Strategic Director. He was founding partner and Scientific Director of the company Valentia BioPharma and the Institute of Genomic Medicine, both located in the Scientific Park of the University of Valencia. Among other projects, his collaboration with the multinational Life Technologies, in the development of applications of the ultrasecuenciación of genomes through the technology SOLiD stands out.
Among his published research articles, three publications are worthy of mention in the prestigious scientific journal Nature. At present, her research focuses on the development of genomic tools for the genetic diagnosis of hereditary diseases and in biopharmaceutical research to combat rare genetic diseases.
He has been Roche's scientific advisor in the field of DNA sequencing. For twelve years, from its foundation in 1998 to April 2009, it has been the promoter and founding partner of the company Sistemas Genómicos SL, where he held the position of Scientific and Strategic Director. He was founding partner and Scientific Director of the company Valentia BioPharma and the Institute of Genomic Medicine, both located in the Scientific Park of the University of Valencia. Among other projects, his collaboration with the multinational Life Technologies, in the development of applications of the ultrasecuenciación of genomes through the technology SOLiD stands out.
Among his published research articles, three publications are worthy of mention in the prestigious scientific journal Nature. At present, her research focuses on the development of genomic tools for the genetic diagnosis of hereditary diseases and in biopharmaceutical research to combat rare genetic diseases.
D. Manuel Sarasa Barrio
Catedratic of Comparative Anatomy and Pathology.
Catedratic Professor of Comparative Anatomy and Pathology of the University of Zaragoza with more than 30 years of experience in basic research and more than 20 years of research on issues related to Alzheimer's disease. Founder of Araclon Biotech in 2004. Inventor of several biotechnology patents related to the diagnosis and treatment of Alzheimer's disease. More than fifty scientific publications with international impact. More than thirty-five gene sequences reported on GenBank. Researcher responsible for more than one research project research (since 1989). Director / founder of the Laboratory of Neurobiology at the University of Zaragoza (1993-2007). Awarded Aragonés of the Year 2004 in Science and Research and as Altoaragonés of the Year in 2009. Awarded by the Spanish Confederation of Alzheimer's Disease and Other Dementias (CEAFA), Research modality in 2009. Numerary Academic by the Royal Academy of Medicine of Zaragoza Since 2-October-2014
Our Patents
We have an exclusive license to exploit the CSIC patent of invention entitled "Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy". This patent has been granted in the USA, Japan and the European Union.
In addition, our propietary patent entitled "Method to determine the risk of developing Alzheimer's disease" has entered into national phases in the USA, Japan and European Union. This patent has already been granted in Spain.
Partners
